Skip to main content

Stream every public session from the 27th annual Global Conference right here on our website.

Nisa Leung

< Back to previous page

Nisa Leung

Managing Director, Qiming Venture Partners
Nisa Leung

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 480 portfolio companies. She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Venus MedTech (HKSE:2500), dMed, Chain Medical Labs, Berry Oncology, Belief BioMed, ZhenGe, Valgen among others. Her other investments include Gan & Lee (SSE:603087), New Horizon Health (HKSE:6606), Aeonmed Medical, Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Wuxi Leiming, MedX, Cure Genetics, Goodwill (SSE:688246), SinoCell Tech (SSE:688520), Sino Biological (SZSE:301047), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR) , Shouti, Jacobio (HKSE:1167), Hope Medicine, Insilico Medicine, Alamar among others. Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022 and named Best Women VCs List by Forbes China (#1 in 2022, #2 in 2021). Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.